Eiger BioPharmaceuticals, Inc.-Product Pipeline Review-2015

Eiger BioPharmaceuticals, Inc.-Product Pipeline Review-2015

  • Products Id :- GMDHC07501CDB
  • |
  • Pages: 27
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Eiger BioPharmaceuticals, Inc.-Product Pipeline Review-2015


Global Markets Direct's, 'Eiger BioPharmaceuticals, Inc.-Product Pipeline Review-2015', provides an overview of the Eiger BioPharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Eiger BioPharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Eiger BioPharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Eiger BioPharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Eiger BioPharmaceuticals, Inc.'s pipeline products

Reasons To Buy

Evaluate Eiger BioPharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Eiger BioPharmaceuticals, Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Eiger BioPharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Eiger BioPharmaceuticals, Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Eiger BioPharmaceuticals, Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Eiger BioPharmaceuticals, Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Eiger BioPharmaceuticals, Inc. Snapshot 5

Eiger BioPharmaceuticals, Inc. Overview 5

Key Information 5

Key Facts 5

Eiger BioPharmaceuticals, Inc.-Research and Development Overview 6

Key Therapeutic Areas 6

Eiger BioPharmaceuticals, Inc.-Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products-Monotherapy 9

Pipeline Products-Partnered Products 10

Partnered Products/Combination Treatment Modalities 11

Eiger BioPharmaceuticals, Inc.-Pipeline Products Glance 12

Eiger BioPharmaceuticals, Inc.-Clinical Stage Pipeline Products 12

Phase II Products/Combination Treatment Modalities 12

Eiger BioPharmaceuticals, Inc.-Drug Profiles 13

EBP-921 13

Product Description 13

Mechanism of Action 13

R&D Progress 13

EBP-922 14

Product Description 14

Mechanism of Action 14

R&D Progress 14

lonafarnib 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

tipifarnib 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

Eiger BioPharmaceuticals, Inc.-Pipeline Analysis 18

Eiger BioPharmaceuticals, Inc.-Pipeline Products by Target 18

Eiger BioPharmaceuticals, Inc.-Pipeline Products by Route of Administration 19

Eiger BioPharmaceuticals, Inc.-Pipeline Products by Molecule Type 20

Eiger BioPharmaceuticals, Inc.-Pipeline Products by Mechanism of Action 21

Eiger BioPharmaceuticals, Inc.-Recent Pipeline Updates 22

Eiger BioPharmaceuticals, Inc.-Dormant Projects 24

Eiger BioPharmaceuticals, Inc.-Locations And Subsidiaries 25

Head Office 25

Appendix 26

Methodology 26

Coverage 26

Secondary Research 26

Primary Research 26

Expert Panel Validation 26

Contact Us 26

Disclaimer 27

List of Tables

Eiger BioPharmaceuticals, Inc., Key Information 5

Eiger BioPharmaceuticals, Inc., Key Facts 5

Eiger BioPharmaceuticals, Inc.-Pipeline by Indication, 2015 7

Eiger BioPharmaceuticals, Inc.-Pipeline by Stage of Development, 2015 8

Eiger BioPharmaceuticals, Inc.-Monotherapy Products in Pipeline, 2015 9

Eiger BioPharmaceuticals, Inc.-Partnered Products in Pipeline, 2015 10

Eiger BioPharmaceuticals, Inc.-Partnered Products/ Combination Treatment Modalities, 2015 11

Eiger BioPharmaceuticals, Inc.-Phase II, 2015 12

Eiger BioPharmaceuticals, Inc.-Pipeline by Target, 2015 18

Eiger BioPharmaceuticals, Inc.-Pipeline by Route of Administration, 2015 19

Eiger BioPharmaceuticals, Inc.-Pipeline by Molecule Type, 2015 20

Eiger BioPharmaceuticals, Inc.-Pipeline Products by Mechanism of Action, 2015 21

Eiger BioPharmaceuticals, Inc.-Recent Pipeline Updates, 2015 22

Eiger BioPharmaceuticals, Inc.-Dormant Developmental Projects,2015 24

List of Figures

Eiger BioPharmaceuticals, Inc.-Partnered Products in Pipeline, 2015 10

Eiger BioPharmaceuticals, Inc.-Pipeline by Top 10 Target, 2015 18

Eiger BioPharmaceuticals, Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 21

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Current R&D Portfolio of Eiger BioPharmaceuticals, Inc.; Eiger BioPharmaceuticals, Inc. - Key Therapeutics; Eiger BioPharmaceuticals, Inc. - Pipeline Overview and Promising Molecules; Eiger BioPharmaceuticals, Inc. - News; Eiger BioPharmaceuticals, Inc. - Latest Updates; Eiger BioPharmaceuticals, Inc. - Pipeline; Eiger BioPharmaceuticals, Inc. - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 107820
Site License
USD 3000 INR 215640
Corporate User License
USD 4500 INR 323460



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com